黄芪注射液与低分子肝素治疗缺血性脑血管病的临床观察

Observation of ischemic cerebrovascular disease treated by Huangqi Zhusheye combined Low Molecular Heparin Clinical

目的观察黄芪注射液合用低分子肝素对急性缺血性脑血管病的治疗作用。方法将临床94例急性缺血性脑血管病病人随机分为两组,即肝黄组和肝素组。肝黄组49例,采用黄芪注射液合用低分子肝素治疗;肝素组45例,采用低分子肝素治疗。观察两组NIHSS和ADL评分、临床疗效、血液流变学指标等。结果肝黄组的NIHSS和ADL评分、临床疗效、血液流变学指标明显优于单用低分子肝素组(P<0.05)。结论黄芪注射液合用低分子肝素治疗急性缺血性脑血管病较单用低分子素治疗优越。

Objective To investigate the therapeutical effect of Huangqi Zhusheye combined Low Molecular Heparin on acute ischemic cerebrovascular disease. Methods 94 cases of acute ischemic cerebrovascular disease were divided randomly to 2 groups, Ganhuang group and Heparin group. Ganhuang group（ 49 cases） were treated by Huangqi Zhusheye combined Low Molecular Heparin, Heparin group （45 cases） were treated by Low Molecular Heparin. The NIHSS, ADL scores , clinical therapeutic effect and haemorheology were observed and compared. Result The NIHSS, ADL scores , clinical therapeutic effect and haemorheology of Ganhuang group＇s surpassed than the Heparin group＇s（P〈0.05）. Conclusion There＇re have an advantage when Huangqi Zhusheye combined Low Molecular Heparin on acute ischemic cerebrovascular disease than applied Low Molecular Heparin alone.